# The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population

## Metadata
**Authors:** Susan I Vear, Gregory D Ayers, Sara L Van Driest, Robert F Sidonio, C Michael Stein, Richard H Ho
**Journal:** British journal of haematology
**Date:** 2014 Mar 6
**DOI:** [10.1111/bjh.12817](https://doi.org/10.1111/bjh.12817)
**PMID:** 24601977
**PMCID:** PMC4043918
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043918/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC4043918/pdf/nihms571135.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC4043918/pdf/nihms571135.pdf)

## Abstract

The influence of genetic variation on warfarin dose requirement is limited for paediatric patients. We performed a retrospective, cross-sectional study to examine the effect of variant CYP2C9 and VKORC1 genotypes on warfarin dose in 100 children. Those with VKORC1 genotype AA required 48% of the dose of homozygous wild-type (GG, p<0.0001). Patients with any variant CYP2C9 allele required 71% of the dose for wild-type (p=0.001). The effect of variant VKORC1 alleles tended to vary with age, suggesting developmental ontogeny may influence warfarin sensitivity. Age, CYP2C9 genotype, VKORC1 genotype and age:VKORC1 interaction accounted for 53% of warfarin dose variability.

Keywords: warfarin, paediatrics, pharmacogenomics, CYP2C9, VKORC1

## Supplementary Material

## Acknowledgments

The authors wish to thank the patients and their parents for generously agreeing to participate in the study, as well as the clinic and research staff who made this study possible. We are also grateful to Prince Kannankeril for his contribution of DNA samples, Dan Roden and the VESPA team and Erica Bowton, together with the rest of the BioVU resource staff.

The project described was supported by grants from the NIH/NHLBI (U19-HL065962 to DR), NCRR/NIH (UL1 RR024975 supporting SIV), and NIH/NIGMS (RC2 GM092618 to DR, 5T32 GM007569-33 to CMS, supporting SIV and SLV, R01 GM10945 to CMS, and R01 GM099924 to RH). The project was also supported by CTSA award No. UL1TR000445 from the National Center for Advancing Translational Sciences.

## Footnotes

## Associated Data

*This section collects any data citations, data availability statements, or supplementary materials included in this article.*

### Supplementary Materials

### Supplementary Materials

## References

1. Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, Leathart JBS, Hanley JP, Daly AK, Kamali F. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood. 2012;119:868–873. doi: 10.1182/blood-2011-08-372722.  [DOI](https://doi.org/10.1182/blood-2011-08-372722) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22010099/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=VKORC1%20and%20CYP2C9%20genotype%20and%20patient%20characteristics%20explain%20a%20large%20proportion%20of%20the%20variability%20in%20warfarin%20dose%20requirement%20among%20children&author=TT%20Biss&author=PJ%20Avery&author=LR%20Brandao&author=EA%20Chalmers&author=MD%20Williams&volume=119&publication_year=2012&pages=868-873&pmid=22010099&doi=10.1182/blood-2011-08-372722&)

2. Cresteil T, Beaune P, Kremers P, Celier C, Guengerich FP, Leroux JP. Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes. European Journal of Biochemistry / FEBS. 1985;151:345–350. doi: 10.1111/j.1432-1033.1985.tb09107.x.  [DOI](https://doi.org/10.1111/j.1432-1033.1985.tb09107.x) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/2411555/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=European%20Journal%20of%20Biochemistry%20/%20FEBS&title=Immunoquantification%20of%20epoxide%20hydrolase%20and%20cytochrome%20P-450%20isozymes%20in%20fetal%20and%20adult%20human%20liver%20microsomes&author=T%20Cresteil&author=P%20Beaune&author=P%20Kremers&author=C%20Celier&author=FP%20Guengerich&volume=151&publication_year=1985&pages=345-350&pmid=2411555&doi=10.1111/j.1432-1033.1985.tb09107.x&)

3. Hirai K, Hayashi H, Ono Y, Izumiya K, Tanaka M, Suzuki T, Sakamoto T, Itoh K. Influence of CYP4F2 Polymorphisms and Plasma Vitamin K Levels on Warfarin Sensitivity in Japanese Pediatric Patients. Drug Metabolism and Pharmacokinetics. 2013;28:132–137. doi: 10.2133/dmpk.dmpk-12-rg-078.  [DOI](https://doi.org/10.2133/dmpk.dmpk-12-rg-078) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22892446/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drug%20Metabolism%20and%20Pharmacokinetics&title=Influence%20of%20CYP4F2%20Polymorphisms%20and%20Plasma%20Vitamin%20K%20Levels%20on%20Warfarin%20Sensitivity%20in%20Japanese%20Pediatric%20Patients&author=K%20Hirai&author=H%20Hayashi&author=Y%20Ono&author=K%20Izumiya&author=M%20Tanaka&volume=28&publication_year=2013&pages=132-137&pmid=22892446&doi=10.2133/dmpk.dmpk-12-rg-078&)

4. Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MTM, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology and Therapeutics. 2011;90:625–629. doi: 10.1038/clpt.2011.185.  [DOI](https://doi.org/10.1038/clpt.2011.185) | [PMC free article](/articles/PMC3187550/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/21900891/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clinical%20Pharmacology%20and%20Therapeutics&title=Clinical%20Pharmacogenetics%20Implementation%20Consortium%20Guidelines%20for%20CYP2C9%20and%20VKORC1%20Genotypes%20and%20Warfarin%20Dosing&author=JA%20Johnson&author=L%20Gong&author=M%20Whirl-Carrillo&author=BF%20Gage&author=SA%20Scott&volume=90&publication_year=2011&pages=625-629&pmid=21900891&doi=10.1038/clpt.2011.185&)

5. Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, Michelson AD. Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133:887S–968S. doi: 10.1378/chest.08-0762.  [DOI](https://doi.org/10.1378/chest.08-0762) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18574281/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Chest&title=Antithrombotic%20Therapy%20in%20Neonates%20and%20Children:%20American%20College%20of%20Chest%20Physicians%20Evidence-Based%20Clinical%20Practice%20Guidelines%20(8th%20Edition)&author=P%20Monagle&author=E%20Chalmers&author=A%20Chan&author=G%20deVeber&author=F%20Kirkham&volume=133&publication_year=2008&pages=887S-968S&pmid=18574281&doi=10.1378/chest.08-0762&)

6. Moreau C, Bajolle F, Siguret V, Lasne D, Golmard JL, Elie C, Beaune P, Cheurfi R, Bonnet D, Loriot MA. Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood. 2012;119:861–867. doi: 10.1182/blood-2011-07-365502.  [DOI](https://doi.org/10.1182/blood-2011-07-365502) | [PMC free article](/articles/PMC3384479/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22130800/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=Vitamin%20K%20antagonists%20in%20children%20with%20heart%20disease:%20height%20and%20VKORC1%20genotype%20are%20the%20main%20determinants%20of%20the%20warfarin%20dose%20requirement&author=C%20Moreau&author=F%20Bajolle&author=V%20Siguret&author=D%20Lasne&author=JL%20Golmard&volume=119&publication_year=2012&pages=861-867&pmid=22130800&doi=10.1182/blood-2011-07-365502&)

7. Nguyen N, Anley P, Yu MY, Zhang G, Thompson AA, Jennings LJ. Genetic and Clinical Determinants Influencing Warfarin Dosing in Children With Heart Disease. Pediatric Cardiology. 2012;34:984–90. doi: 10.1007/s00246-012-0592-1.  [DOI](https://doi.org/10.1007/s00246-012-0592-1) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23183958/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pediatric%20Cardiology&title=Genetic%20and%20Clinical%20Determinants%20Influencing%20Warfarin%20Dosing%20in%20Children%20With%20Heart%20Disease&author=N%20Nguyen&author=P%20Anley&author=MY%20Yu&author=G%20Zhang&author=AA%20Thompson&volume=34&publication_year=2012&pages=984-90&pmid=23183958&doi=10.1007/s00246-012-0592-1&)

8. Nowak-Gottl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C, Mitchell LG. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 2010;116:6101–6105. doi: 10.1182/blood-2010-05-283861.  [DOI](https://doi.org/10.1182/blood-2010-05-283861) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20833980/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=In%20pediatric%20patients,%20age%20has%20more%20impact%20on%20dosing%20of%20vitamin%20K%20antagonists%20than%20VKORC1%20or%20CYP2C9%20genotypes&author=U%20Nowak-Gottl&author=K%20Dietrich&author=D%20Schaffranek&author=NS%20Eldin&author=Y%20Yasui&volume=116&publication_year=2010&pages=6101-6105&pmid=20833980&doi=10.1182/blood-2010-05-283861&)

9. Oldenburg J, Bevans CG, Müller CR, Watzka M. Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1): The Key Protein of the Vitamin K Cycle. Antioxidants & Redox Signaling. 2006;8:347–353. doi: 10.1089/ars.2006.8.347.  [DOI](https://doi.org/10.1089/ars.2006.8.347) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/16677080/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Antioxidants%20&%20Redox%20Signaling&title=Vitamin%20K%20Epoxide%20Reductase%20Complex%20Subunit%201%20(VKORC1):%20The%20Key%20Protein%20of%20the%20Vitamin%20K%20Cycle&author=J%20Oldenburg&author=CG%20Bevans&author=CR%20M%C3%BCller&author=M%20Watzka&volume=8&publication_year=2006&pages=347-353&pmid=16677080&doi=10.1089/ars.2006.8.347&)

10. Owen RP, Gong L, Sagreiya H, Klein TE, Altman RB. VKORC1 Pharmacogenomics Summary. Pharmacogenetics and Genomics. 2010;20:642–644. doi: 10.1097/FPC.0b013e32833433b6.  [DOI](https://doi.org/10.1097/FPC.0b013e32833433b6) | [PMC free article](/articles/PMC3086043/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19940803/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics%20and%20Genomics&title=VKORC1%20Pharmacogenomics%20Summary&author=RP%20Owen&author=L%20Gong&author=H%20Sagreiya&author=TE%20Klein&author=RB%20Altman&volume=20&publication_year=2010&pages=642-644&pmid=19940803&doi=10.1097/FPC.0b013e32833433b6&)

11. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1Haplotypes on Transcriptional Regulation and Warfarin Dose. The New England Journal of Medicine. 2005;352:2285–2293. doi: 10.1056/NEJMoa044503.  [DOI](https://doi.org/10.1056/NEJMoa044503) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/15930419/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=The%20New%20England%20Journal%20of%20Medicine&title=Effect%20of%20VKORC1Haplotypes%20on%20Transcriptional%20Regulation%20and%20Warfarin%20Dose&author=MJ%20Rieder&author=AP%20Reiner&author=BF%20Gage&author=DA%20Nickerson&author=CS%20Eby&volume=352&publication_year=2005&pages=2285-2293&pmid=15930419&doi=10.1056/NEJMoa044503&)

12. Salem F, Johnson TN, Barter ZE, Leeder JS, Rostami Hodjegan A. Age Related Changes in Fractional Elimination Pathways for Drugs: Assessing the Impact of Variable Ontogeny on Metabolic Drug–Drug Interactions. The Journal of Clinical Pharmacology. 2013;53:857–65. doi: 10.1002/jcph.100.  [DOI](https://doi.org/10.1002/jcph.100) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23720017/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=The%20Journal%20of%20Clinical%20Pharmacology&title=Age%20Related%20Changes%20in%20Fractional%20Elimination%20Pathways%20for%20Drugs:%20Assessing%20the%20Impact%20of%20Variable%20Ontogeny%20on%20Metabolic%20Drug%E2%80%93Drug%20Interactions&author=F%20Salem&author=TN%20Johnson&author=ZE%20Barter&author=JS%20Leeder&author=A%20Rostami%20Hodjegan&volume=53&publication_year=2013&pages=857-65&pmid=23720017&doi=10.1002/jcph.100&)

13. Treluyer JM, Gueret G, Cheron G, Sonnier M, Cresteil T. Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics. 1997;7:441–452. doi: 10.1097/00008571-199712000-00002.  [DOI](https://doi.org/10.1097/00008571-199712000-00002) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9429229/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics&title=Developmental%20expression%20of%20CYP2C%20and%20CYP2C-dependent%20activities%20in%20the%20human%20liver:%20in-vivo/in-vitro%20correlation%20and%20inducibility&author=JM%20Treluyer&author=G%20Gueret&author=G%20Cheron&author=M%20Sonnier&author=T%20Cresteil&volume=7&publication_year=1997&pages=441-452&pmid=9429229&doi=10.1097/00008571-199712000-00002&)

14. Vear SI, Stein CM, Ho RH. Warfarin pharmacogenomics in children. Pediatric Blood & Cancer. 2013;60:1402–1407. doi: 10.1002/pbc.24592.  [DOI](https://doi.org/10.1002/pbc.24592) | [PMC free article](/articles/PMC3786327/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23682017/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pediatric%20Blood%20&%20Cancer&title=Warfarin%20pharmacogenomics%20in%20children&author=SI%20Vear&author=CM%20Stein&author=RH%20Ho&volume=60&publication_year=2013&pages=1402-1407&pmid=23682017&doi=10.1002/pbc.24592&)

15. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis. Thrombosis Research. 2010;125:e159–66. doi: 10.1016/j.thromres.2009.10.017.  [DOI](https://doi.org/10.1016/j.thromres.2009.10.017) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19942260/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Thrombosis%20Research&title=Impact%20of%20VKORC1%20gene%20polymorphism%20on%20interindividual%20and%20interethnic%20warfarin%20dosage%20requirement--a%20systematic%20review%20and%20meta%20analysis&author=L%20Yang&author=W%20Ge&author=F%20Yu&author=H%20Zhu&volume=125&publication_year=2010&pages=e159-66&pmid=19942260&doi=10.1016/j.thromres.2009.10.017&)
